PBLS
Parabilis Medicines, Inc.
Price Chart
Latest Quote
$25.85
-0.18 (-0.69%)
Current Price
| Previous Close | $26.03 |
| Open | $25.98 |
| Day High | $27.00 |
| Day Low | $25.35 |
| Volume | 670,619 |
Stock Information
| Shares Outstanding | 120.73M |
| Total Debt | $53.15M |
| Cash Equivalents | $329.04M |
| Net Income | $-209.71M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.16B |
| EPS (TTM) | $-1.77 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $625.73M |
| Income | $-209.71M |
| Book/sh | $-174.15 |
| Cash/sh | $2.73 |
| Employees | 145 |
Financial Ratios
| Quick Ratio | 6.07 |
| Current Ratio | 6.12 |
| Debt/Eq | 21.76 |
Returns & Margins
Ownership
| Insider Ownership | 3.67% |
| Institutional Ownership | 35.91% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | -0.15 |
Analyst Data
| Recommendation | none |
Technical Indicators
| Shares Float | 3.03M |
Performance History
| Week | -14.71% |
| YTD | -18.20% |
| 10 Years | -18.20% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $25.85 | 684,500 |
| 2026-06-17 | $26.03 | 1,929,200 |
| 2026-06-16 | $26.59 | 3,384,300 |
| 2026-06-15 | $25.01 | 1,280,300 |
| 2026-06-12 | $27.26 | 1,035,500 |
| 2026-06-11 | $30.31 | 1,600,200 |
| 2026-06-10 | $31.60 | 5,496,700 |
About Parabilis Medicines, Inc.
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | ||
| Total Revenue | $0 | $0 |
| Operating Revenue | $0 | $0 |
| Expenses | ||
| Interest Expense | $1,522,000 | $1,486,000 |
| Total Expenses | $152,079,000 | $126,125,000 |
| Other Income Expense | $4,326,000 | $3,289,000 |
| Other Non Operating Income Expenses | $4,326,000 | $3,289,000 |
| Net Non Operating Interest Income Expense | $1,864,000 | $4,922,000 |
| Interest Expense Non Operating | $1,522,000 | $1,486,000 |
| Operating Expense | $152,079,000 | $126,125,000 |
| General And Administrative Expense | $26,496,000 | $25,296,000 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-145,889,000 | $-117,914,000 |
| Net Interest Income | $1,864,000 | $4,922,000 |
| Interest Income | $3,386,000 | $6,408,000 |
| Normalized Income | $-145,889,000 | $-117,914,000 |
| Net Income From Continuing And Discontinued Operation | $-145,889,000 | $-117,914,000 |
| Total Operating Income As Reported | $-152,079,000 | $-126,125,000 |
| Net Income Common Stockholders | $-186,933,000 | $-161,481,000 |
| Net Income | $-145,889,000 | $-117,914,000 |
| Net Income Including Noncontrolling Interests | $-145,889,000 | $-117,914,000 |
| Net Income Continuous Operations | $-145,889,000 | $-117,914,000 |
| Pretax Income | $-145,889,000 | $-117,914,000 |
| Interest Income Non Operating | $3,386,000 | $6,408,000 |
| Operating Income | $-152,079,000 | $-126,125,000 |
| Per Share | ||
| Diluted EPS | $-1.81 | $-2.00 |
| Basic EPS | $-1.81 | $-2.00 |
| Other | ||
| Tax Effect Of Unusual Items | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-141,867,000 | $-114,328,000 |
| Reconciled Depreciation | $2,500,000 | $2,100,000 |
| EBITDA (Bullshit earnings) | $-141,867,000 | $-114,328,000 |
| EBIT | $-144,367,000 | $-116,428,000 |
| Diluted Average Shares | $80,682,852 | $80,709,701 |
| Basic Average Shares | $80,682,852 | $80,709,701 |
| Diluted NI Availto Com Stockholders | $-186,933,000 | $-161,481,000 |
| Preferred Stock Dividends | $41,044,000 | $43,567,000 |
| Research And Development | $125,583,000 | $100,829,000 |
| Selling General And Administration | $26,496,000 | $25,296,000 |
| Other Gand A | $14,856,000 | $13,751,000 |
| Salaries And Wages | $11,640,000 | $11,545,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-16,524,000 | $56,439,000 |
| Total Assets | $80,820,000 | $149,253,000 |
| Total Non Current Assets | $51,462,000 | $57,045,000 |
| Other Non Current Assets | $5,387,000 | $4,117,000 |
| Current Assets | $29,358,000 | $92,208,000 |
| Other Current Assets | $1,647,000 | $3,870,000 |
| Receivables | $0 | $360,000 |
| Cash Cash Equivalents And Short Term Investments | $27,711,000 | $87,978,000 |
| Cash And Cash Equivalents | $27,711,000 | $47,284,000 |
| Debt | ||
| Total Debt | $58,700,000 | $66,198,000 |
| Long Term Debt And Capital Lease Obligation | $37,811,000 | $56,822,000 |
| Current Debt And Capital Lease Obligation | $20,889,000 | $9,376,000 |
| Current Debt | $13,077,000 | $2,500,000 |
| Other Current Borrowings | $13,077,000 | $2,500,000 |
| Long Term Debt | - | $12,788,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $97,344,000 | $92,814,000 |
| Total Non Current Liabilities Net Minority Interest | $40,553,000 | $60,402,000 |
| Other Non Current Liabilities | $2,742,000 | $1,413,000 |
| Current Liabilities | $56,791,000 | $32,412,000 |
| Other Current Liabilities | $1,217,000 | $622,000 |
| Payables And Accrued Expenses | $25,606,000 | $16,065,000 |
| Payables | $17,272,000 | $9,514,000 |
| Accounts Payable | $17,272,000 | $9,514,000 |
| Equity | ||
| Common Stock Equity | $-526,495,000 | $-383,936,000 |
| Preferred Stock Equity | $509,971,000 | $440,375,000 |
| Total Equity Gross Minority Interest | $-16,524,000 | $56,439,000 |
| Stockholders Equity | $-16,524,000 | $56,439,000 |
| Gains Losses Not Affecting Retained Earnings | $0 | $21,000 |
| Retained Earnings | $-541,504,000 | $-395,615,000 |
| Preferred Securities Outside Stock Equity | $0 | $2,167,000 |
| Other Equity Adjustments | - | $21,000 |
| Other | ||
| Ordinary Shares Number | $118,750,719 | $118,750,719 |
| Share Issued | $118,750,719 | $118,750,719 |
| Tangible Book Value | $-526,495,000 | $-383,936,000 |
| Invested Capital | $-513,418,000 | $-368,648,000 |
| Working Capital | $-27,433,000 | $59,796,000 |
| Capital Lease Obligations | $45,623,000 | $50,910,000 |
| Total Capitalization | $-16,524,000 | $69,227,000 |
| Additional Paid In Capital | $15,009,000 | $11,658,000 |
| Capital Stock | $509,971,000 | $440,375,000 |
| Common Stock | $0 | $0 |
| Preferred Stock | $509,971,000 | $440,375,000 |
| Long Term Capital Lease Obligation | $37,811,000 | $44,034,000 |
| Current Capital Lease Obligation | $7,812,000 | $6,876,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $9,079,000 | $6,349,000 |
| Current Accrued Expenses | $8,334,000 | $6,551,000 |
| Net PPE | $46,075,000 | $52,928,000 |
| Accumulated Depreciation | $-12,813,000 | $-10,454,000 |
| Gross PPE | $58,888,000 | $63,382,000 |
| Leases | $4,563,000 | $4,498,000 |
| Other Properties | $53,321,000 | $57,805,000 |
| Machinery Furniture Equipment | $1,004,000 | $1,079,000 |
| Properties | $0 | $0 |
| Duefrom Related Parties Current | $0 | $360,000 |
| Other Short Term Investments | $0 | $40,694,000 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-124,019,000 | $-104,492,000 |
| Operating Activities | ||
| Operating Cash Flow | $-123,713,000 | $-103,613,000 |
| Cash Flow From Continuing Operating Activities | $-123,715,000 | $-103,620,000 |
| Operating Gains Losses | - | $360,000 |
| Investing Activities | ||
| Capital Expenditure | $-306,000 | $-879,000 |
| Investing Cash Flow | $39,758,000 | $30,242,000 |
| Cash Flow From Continuing Investing Activities | $39,758,000 | $30,242,000 |
| Financing Activities | ||
| Repurchase Of Capital Stock | $-62,000 | $-494,000 |
| Issuance Of Capital Stock | $67,491,000 | $77,508,000 |
| Financing Cash Flow | $64,382,000 | $78,068,000 |
| Cash Flow From Continuing Financing Activities | $64,382,000 | $78,068,000 |
| Net Preferred Stock Issuance | $67,429,000 | $77,014,000 |
| Preferred Stock Issuance | $67,491,000 | $77,508,000 |
| Net Other Financing Charges | - | $-17,000 |
| Other | ||
| Repayment Of Debt | $-3,081,000 | $0 |
| Interest Paid Supplemental Data | $1,247,000 | $1,029,000 |
| End Cash Position | $30,566,000 | $50,139,000 |
| Beginning Cash Position | $50,139,000 | $45,442,000 |
| Changes In Cash | $-19,573,000 | $4,697,000 |
| Proceeds From Stock Option Exercised | $34,000 | $1,071,000 |
| Preferred Stock Payments | $-62,000 | $-494,000 |
| Net Issuance Payments Of Debt | $-3,081,000 | $0 |
| Net Long Term Debt Issuance | $-3,081,000 | $0 |
| Long Term Debt Payments | $-3,081,000 | $0 |
| Net Investment Purchase And Sale | $40,064,000 | $31,121,000 |
| Sale Of Investment | $56,728,000 | $121,979,000 |
| Purchase Of Investment | $-16,664,000 | $-90,858,000 |
| Net PPE Purchase And Sale | $-306,000 | $-879,000 |
| Purchase Of PPE | $-306,000 | $-879,000 |
| Change In Working Capital | $9,117,000 | $910,000 |
| Change In Other Current Liabilities | $-6,344,000 | $-5,538,000 |
| Change In Payables And Accrued Expense | $13,590,000 | $8,810,000 |
| Change In Payable | $13,590,000 | $8,810,000 |
| Change In Account Payable | $13,590,000 | $9,284,000 |
| Change In Prepaid Assets | $1,511,000 | $-2,468,000 |
| Change In Receivables | $360,000 | $106,000 |
| Other Non Cash Items | $6,633,000 | $7,230,000 |
| Stock Based Compensation | $3,317,000 | $4,310,000 |
| Amortization Of Securities | $609,000 | $-609,000 |
| Depreciation Amortization Depletion | $2,500,000 | $2,100,000 |
| Depreciation And Amortization | $2,500,000 | $2,100,000 |
| Depreciation | $2,500,000 | $2,100,000 |
| Gain Loss On Sale Of PPE | $0 | $360,000 |
| Net Income From Continuing Operations | $-145,889,000 | $-117,914,000 |
Fetched: 2026-06-17